Why the study?
Pediatric-specific reference limits for hs-cTnI and NT-proBNP using Alinity immunoassays were needed to reduce misinformed clinical decision-making.
Establishing pediatric-specific reference limits for hs-cTnI and NT-proBNP is necessary to reduce misinformed clinical decision-making in children and adolescents.
May aid hs-cTnI/NT-proBNP interpretation in Canadian children; leaves open validation across populations and assays.
We report age-specific reference limits for hs-cTnI and NT-proBNP in a healthy Canadian cohort of children and adolescents measured using Alinity immunoassays for the first time. These data support the need for pediatric-specific interpretation to reduce misinformed clinical decision-making and calls to action larger cohort studies such that reference limits can be more robustly defined.
No takes yet. Share an insight, caveat, or question.
Bohn et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: